Trials / Completed
CompletedNCT01482143
Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Children With Fragile X Syndrome (FXS)
Sequential, Two-period Study to Assess the Pharmacokinetics, Safety & Tolerability of Single and Multiple Oral Doses of AFQ056 in Patients With FXS (Fragile X Syndrome) Aged 5-11 Years (Cohort 1) and 3-4 Years (Cohort 2)
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 21 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 3 Years – 11 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to characterize the pharmacokinetics and safety/tolerability of AFQ056 in children with Fragile X Syndrome(FXS)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AFQ056 |
Timeline
- Start date
- 2012-03-01
- Primary completion
- 2013-10-01
- Completion
- 2013-10-01
- First posted
- 2011-11-30
- Last updated
- 2020-12-08
Locations
4 sites across 2 countries: United States, Spain
Source: ClinicalTrials.gov record NCT01482143. Inclusion in this directory is not an endorsement.